RPL14

Large ribosomal subunit protein eL14 · P50914 · RPL14 on Sugi Atlas →

3,633 patent compounds predicted against RPL14, 1,896 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL14 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer	PHASE2	COMPLETED
Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Quantification of GADD34 Expression in RA	nan	COMPLETED
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Study of Proteins in Head and Neck Cancer Cells	nan	COMPLETED
Somatosensory Modulation of Salivary Gene Expression and Oral Feeding in Preterm Infants	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RPL14 binder may also engage these)

Protein	Name	Similarity
Q3T0U2	—	0.997	Q3T0U2 →
Q63507	—	0.990	Q63507 →
A1XQU3	—	0.988	A1XQU3 →
G1SZ12	—	0.987	G1SZ12 →
Q9CR57	—	0.986	Q9CR57 →
Q58DQ3	—	0.943	Q58DQ3 →
Q6QMZ4	—	0.941	Q6QMZ4 →
P21533	—	0.941	P21533 →
Q90YU3	—	0.940	Q90YU3 →
Q2YGT9	—	0.940	Q2YGT9 →
Q6Y263	—	0.940	Q6Y263 →
P83732	—	0.939	P83732 →
G1SE28	—	0.939	G1SE28 →
RPL24	Large ribosomal subunit protein eL24	0.939	landscape →
RPL6	Large ribosomal subunit protein eL6	0.939	landscape →
P47911	—	0.938	P47911 →
Q9DFQ7	—	0.938	Q9DFQ7 →
P61122	—	0.937	P61122 →
G1SKF7	—	0.936	G1SKF7 →
Q862I1	—	0.935	Q862I1 →
Q8BP67	—	0.935	Q8BP67 →
Q4R5C7	—	0.933	Q4R5C7 →
Q42347	—	0.932	Q42347 →
Q66WF5	—	0.932	Q66WF5 →
Q8JGR4	—	0.931	Q8JGR4 →
P38666	—	0.930	P38666 →
P50888	—	0.928	P50888 →
P55844	—	0.928	P55844 →
Q9T043	—	0.927	Q9T043 →
O65743	—	0.926	O65743 →